Eflornithine ( DrugBank: Eflornithine )


1 disease
IDDisease name (Link within this page)Number of trials
65Primary immunodeficiency5

65. Primary immunodeficiency


Clinical trials : 500 Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01685827
(ClinicalTrials.gov)
October 201212/9/2012Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label StudyHuman African Trypanosomiasis (HAT);Sleeping SicknessDrug: Fexinidazole;Drug: Nifurtimox;Drug: EflornithineDrugs for Neglected DiseasesNULLCompleted15 YearsN/AAll394Phase 2/Phase 3Central African Republic;Congo, The Democratic Republic of the;Congo
2NCT00906880
(ClinicalTrials.gov)
April 200919/5/2009Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic PhaseClinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic StageHuman African TrypanosomiasisDrug: Nifurtimox-Eflronithine Combination Treatment (NECT)Drugs for Neglected DiseasesMinistry of Public Health, Democratic Republic of the Congo;Swiss Tropical & Public Health InstituteCompletedN/AN/ABoth630Phase 4Congo
3NCT00146627
(ClinicalTrials.gov)
September 20046/9/2005Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African TrypanosomiasisClinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic PhaseTrypanosomiasis, AfricanDrug: Eflornithine;Drug: NifurtimoxDrugs for Neglected DiseasesMedecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical & Public Health Institute;World Health Organization;Medecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical & Public Health Institute;World Health OrganizationCompleted15 Years70 YearsBoth280Phase 3Congo, The Democratic Republic of the;Congo;The Democratic Republic of the Congo;Uganda
4NCT00489658
(ClinicalTrials.gov)
October 200220/6/2007Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, UgandaEfficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, UgandaTrypanosomiasis, AfricanDrug: Eflornithine plus Nifurtimox combination therapyEpicentreMedecins Sans FrontieresTerminatedN/AN/ABoth31Phase 2/Phase 3Uganda
5NCT00330148
(ClinicalTrials.gov)
March 200124/5/2006Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African TrypanosomiasisClinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic PhaseTrypanosomiasis, AfricanDrug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;Drug: melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;Drug: nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7dEpicentreMedecins Sans Frontieres;Embassy of France in Uganda;National Sleeping Sickness Control Program, UgandaTerminatedN/AN/ABoth435Phase 3Uganda